Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
7 hedge funds and large institutions have $10.9M invested in Celyad Oncology SA American Depositary Shares in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
3% more capital invested
Capital invested by funds: $10.6M → $10.9M (+$284K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$8.49M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$303K |
| 3 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
+$14.5K |
| 4 |
Morgan Stanley
New York
|
+$7.13K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.69K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Victory Capital Management
San Antonio,
Texas
| $8.29M | +$8.49M | +351,313 | New |
|
|
CAM
2
Cormorant Asset Management
Boston,
Massachusetts
| $1.79M | – | – | – |
|
|
3
Zurich Cantonal Bank
Zurich,
Switzerland
| $419K | +$14.5K | +600 | +3% |
|
|
DCM
4
DAFNA Capital Management
Los Angeles,
California
| $296K | +$303K | +12,528 | New |
|
|
5
Morgan Stanley
New York
| $50K | +$7.13K | +295 | +16% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $8K | – | – | – |
|
|
7
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$1.69K | +70 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$13K | -522 | Closed |
|
CYAD Hedge Fund Activity: Q3 2016 in Review
7 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q3 2016, worth a combined $10.9M — up 2.7% from $10.6M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CYAD positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Victory Capital Management, opening a new position worth an estimated $8.49M. The largest seller was UBS Group, exiting entirely with an estimated $13K sold.
- 7 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q3 2016, up from 6 in Q2 2016.
- Funds reported $10.9M of Celyad Oncology SA American Depositary Shares stock for Q3 2016, up 2.7% quarter-over-quarter.
- 3 funds opened new Celyad Oncology SA American Depositary Shares positions in Q3 2016 and 1 closed out, a net change of +2 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q3 2016 was Victory Capital Management, an estimated $8.49M added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q3 2016 was UBS Group, an estimated $13K sold.
Based on aggregated 13F filings for Q3 2016.